Summary of Clinical Use

Sonelokimab was progressed to clinical evaluations to determine safety and efficacy in psoriasis, psoriatic arthritis and hidradenitis suppurativa [2]. In one of two phase 3 trials sonelokimab failed to demonstrate clinical benefit above placebo in patients with moderate to severe hidradenitis suppurativa.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT05322473	Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa	Phase 2 Interventional	MoonLake Immunotherapeutics AG
NCT05640245	Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis	Phase 2 Interventional	MoonLake Immunotherapeutics AG
NCT06411379	Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 3 Interventional	MoonLake Immunotherapeutics AG	The VELA-2 study: A higher-than-expected placebo response rate in this study meant that it missed the predetermined endpoint.
NCT07007637	A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 3 Interventional	MoonLake Immunotherapeutics AG
NCT06411899	A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	Phase 3 Interventional	MoonLake Immunotherapeutics AG	The VELA-1 study
NCT02156466	Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects	Phase 1 Interventional	Merck KGaA, Darmstadt, Germany		4
NCT03384745	A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis	Phase 2 Interventional	Bond Avillion 2 Development LP		3